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INTRODUCTION
• Teriflunomide and dimethyl fumarate (DMF) have both demonstrated efficacy as oral therapies in a number of clinical trials in patients with relapsing-remitting MS
• Despite the well-known challenges in comparing outcomes across trials, this is often done on the basis of relative reductions in a specific endpoint (eg, relapse rate)
• However, these comparisons do not take into account differences in patient populations in clinical studies, which may affect the interpretation from inter-study comparisons. Relative risk reductions may also over-represent treatment effects when the frequency of the event is low 1 • Evidence-based medicine often utilizes approaches such as absolute risk reduction and number needed to treat (NNT) to get a fuller understanding of clinical outcomes -NNT takes into account not only the treatment effect but also the rarity of the event in question (eg, relapse); thus, a higher NNT would be expected if fewer patients experienced the event in the time period of interest
• The MS population has evolved over time with a downward trend in relapse rates, largely as a result of improved techniques for earlier diagnosis of MS. Here, we report the results of 2 recently studied oral treatments for MS using NNT/absolute risk reduction 
METHODS

Study Designs
• All 4 studies were phase 3, randomized, placebo-controlled, multinational trials evaluating teriflunomide (14 mg or 7 mg/day vs placebo) or DMF (240 mg twice-or three-times daily vs placebo [DEFINE] or placebo or glatiramer acetate [CONFIRM] ) in patients with relapsing forms of MS. The primary endpoint was annualized relapse rate (ARR; in TEMSO, TOWER, CONFIRM) or the proportion of patients who had relapsed by 2 years (in DEFINE) ( Table 1) Calculation of NNT
• In a post hoc analysis, the NNT to prevent 1 relapse, or 1 relapse leading to hospitalization, was calculated from the inverse of the risk difference (absolute risk) of ARR in the placebo group (ARRp) and the active treatment group (ARRa):
• The NNT to prevent 1 patient from experiencing disability progression was calculated using the Altman derivation, 6 taking into account the survival probabilities in the placebo and active treatment groups:
-The survival probability in the placebo group, Sc(t), is equal to 1 -the probability of disability progression confirmed for
Teriflunomide is approved in many countries, including the US and the European Union, for the treatment of relapsing multiple sclerosis or relapsing-remitting multiple sclerosis. This material may contain information that is outside of the approved labeling in some countries.
CONCLUSIONS
• NNT is an approach that can help compare results across clinical trials. Using the NNT approach, we demonstrate a comparable effect size for teriflunomide and DMF on relapse • NNTs to prevent relapses leading to hospitalization were lower in the teriflunomide studies than in the DMF studies • NNTs for prevention of disability progression were comparable for TEMSO, TOWER, and DEFINE, but not CONFIRM. Only teriflunomide showed consistent, significant reductions in risk of disability progression in 2 phase 3 studies
RESULTS
Patients
• Patient demographics and baseline disease characteristics were generally similar across all teriflunomide and DMF studies ( 
NNT to Prevent 1 Relapse
• Teriflunomide and DMF significantly reduced risk of relapse vs placebo in all studies; a higher relative risk reduction was observed for DMF, but similar absolute differences/NNTs to prevent 1 relapse were observed across studies for both products (Table 3) NNT to Prevent 1 Patient Experiencing Disability Progression
• Risk of disability progression sustained for 12 weeks was significantly reduced vs placebo in the 2 teriflunomide studies, and in 1 of the DMF studies ( 
NNT to Prevent 1 Relapse Leading to Hospitalization
• Risk of relapse leading to hospitalization was significantly reduced vs placebo in both teriflunomide studies, but not in the DMF studies
